| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $15,975 | 4 | 100 |
| Neri Jesse | SVP and CFO | 0 | $0 | 1 | $740 | $-740 |
| Hunter Heather | Chief Operating Officer | 0 | $0 | 1 | $2,396 | $-2,396 |
| COOPER JOHN G | director | 0 | $0 | 1 | $4,419 | $-4,419 |
| Strobeck Mark | President and CEO | 0 | $0 | 1 | $8,420 | $-8,420 |
Rockwell Medical, Inc., together with its associated companies, operates as a biopharmaceutical firm specializing in treatments for chronic and end-stage kidney disease. The company provides a range of therapies and products aimed at addressing iron deficiency and supporting hemodialysis procedures, serving markets both within the United States and internationally. A key offering includes its Triferic line (Triferic Dialysate and Triferic AVNU), an innovative iron replacement therapy. This therapy is designed to replenish iron and maintain …
Over the last 12 months, insiders at Rockwell Medical, Inc. have bought $0 and sold $15,975 worth of Rockwell Medical, Inc. stock.
On average, over the past 5 years, insiders at Rockwell Medical, Inc. have bought $94,018 and sold $46,981 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 30,500 shares for transaction amount of $32,982 was made by Irrevocable Larson Family Investment Trust (10 percent owner) on 2025‑04‑11.
| 2026-10-01 | Sale | Strobeck Mark | President and CEO | 1,000 0.0248% | $8.42 | $8,420 | -12.60% | |
| 2026-01-02 | Sale | Hunter Heather | Chief Operating Officer | 2,868 0.0084% | $0.84 | $2,396 | -6.20% | |
| 2026-01-02 | Sale | Neri Jesse | SVP and CFO | 886 0.0026% | $0.84 | $740 | -6.20% | |
| 2025-11-18 | Sale | COOPER JOHN G | director | 5,079 0.0147% | $0.87 | $4,419 | -4.69% | |
| 2025-10-01 | Sale | Strobeck Mark | President and CEO | 6,926 0.0199% | $1.19 | $8,242 | -26.89% | |
| 2025-10-01 | Sale | Hunter Heather | SVP, Chief Operating Officer | 2,868 0.0083% | $1.19 | $3,413 | -26.89% | |
| 2025-10-01 | Sale | Neri Jesse | SVP and CFO | 886 0.0026% | $1.19 | $1,054 | -26.89% | |
| 2025-10-01 | Sale | Chole Timothy | SVP and CCO | 2,868 0.0083% | $1.19 | $3,413 | -26.89% | |
| 2025-07-01 | Sale | Strobeck Mark | President and CEO | 6,926 0.02% | $0.82 | $5,679 | +15.16% | |
| 2025-07-01 | Sale | Chole Timothy | SVP and CCO | 2,868 0.0083% | $0.82 | $2,352 | +15.16% | |
| 2025-07-01 | Sale | Neri Jesse | SVP and CFO | 886 0.0026% | $0.82 | $727 | +15.16% | |
| 2025-04-11 | Irrevocable Larson Family Investment Trust | 10 percent owner | 30,500 0.0997% | $1.08 | $32,982 | -3.77% | ||
| 2025-04-10 | Irrevocable Larson Family Investment Trust | 10 percent owner | 57,000 0.1846% | $1.07 | $61,036 | -4.67% | ||
| 2025-04-01 | Sale | Strobeck Mark | President and CEO | 6,926 0.0203% | $1.08 | $7,480 | -4.63% | |
| 2025-04-01 | Sale | Chole Timothy | SVP, Chief Commercial Officer | 2,868 0.0084% | $1.08 | $3,097 | -4.63% | |
| 2025-04-01 | Sale | Neri Jesse | SVP, FINANCE AND CFO | 886 0.0026% | $1.10 | $975 | -4.63% | |
| 2025-01-02 | Sale | Strobeck Mark | President and CEO | 2,163 0.0062% | $2.06 | $4,445 | -50.00% | |
| 2025-01-02 | Sale | Chole Timothy | SVP, Chief Commercial Officer | 1,001 0.0029% | $2.05 | $2,052 | -50.00% | |
| 2024-11-15 | Sale | RAVICH MARK H | director | 29,991 0.0915% | $2.35 | $70,379 | -49.58% | |
| 2024-10-01 | Sale | Strobeck Mark | President and CEO | 2,163 0.0068% | $3.69 | $7,971 | -56.66% |
| Irrevocable Larson Family Investment Trust | 10 percent owner | 3557500 88.2652% | $28.78M | 2 | 0 | <0.0001% |
| CHIOINI ROBERT L | Chairman, President and CEO | 1793933 44.5093% | $14.51M | 2 | 9 | <0.0001% |
| Richmond David S. | 10 percent owner | 1433309 35.5619% | $11.6M | 16 | 4 | <0.0001% |
| HAGELSTEIN DAVID A | 10 percent owner | 1360700 33.7604% | $11.01M | 34 | 4 | |
| Paul Stuart M | Chief Executive Officer | 363798 9.0262% | $2.94M | 1 | 0 | <0.0001% |
| Gupta Ajay | Chief Scientific Officer | 326667 8.1049% | $2.64M | 1 | 0 | <0.0001% |
| Smith Angus W. | Chief Financial Officer | 176667 4.3833% | $1.43M | 1 | 0 | <0.0001% |
| Pratt Raymond Dennis | VP of Drug Development | 160700 3.9871% | $1.3M | 1 | 0 | <0.0001% |
| ELLISON RUSSELL H | See Remarks | 12050 0.299% | $97,484.50 | 1 | 0 | <0.0001% |
$2,101,005 | 2135 | -11.51% | $64.58M | |
$131,310,609 | 62 | 26.99% | $107.44M | |
$2,767,882 | 51 | 8.70% | $24.78M | |
$30,221,759 | 51 | 0.50% | $20.6M | |
$33,884,330 | 45 | 12.56% | $223.45M |
| Increased Positions | 16 | +36.36% | 497,233 | +14.82% |
| Decreased Positions | 17 | -38.64% | 357,429 | -10.66% |
| New Positions | 6 | New | 203,350 | New |
| Sold Out Positions | 7 | Sold Out | 234,960 | Sold Out |
| Total Postitions | 43 | -2.27% | 3M | +4.17% |
| Vanguard Group Inc | $1,169.00 | 3.47% | 1.35M | +148,737 | +12.34% | 2025-09-30 |
| Renaissance Technologies Llc | $485.00 | 1.44% | 562,205 | +20,454 | +3.78% | 2025-09-30 |
| Geode Capital Management, Llc | $279.00 | 0.83% | 323,148 | +2,483 | +0.77% | 2025-09-30 |
| Blackrock, Inc. | $192.00 | 0.57% | 222,149 | -1,565 | -0.7% | 2025-09-30 |
| Gsa Capital Partners Llp | $142.00 | 0.42% | 163,978 | +141,672 | +635.13% | 2025-09-30 |
| State Street Corp | $87.00 | 0.26% | 100,904 | 0 | 0% | 2025-09-30 |
| Hightower Advisors, Llc | $81.00 | 0.24% | 93,524 | 0 | 0% | 2025-09-30 |
| Northern Trust Corp | $71.00 | 0.21% | 82,133 | +18,741 | +29.56% | 2025-09-30 |
| Perkins Capital Management Inc | $62.00 | 0.18% | 71,922 | 0 | 0% | 2025-09-30 |
| Panagora Asset Management Inc | $59.00 | 0.18% | 68,562 | +20,164 | +41.66% | 2025-09-30 |